VRX acquires SURG for $6.50/sh in cash plus contingencies—a 48% premium to SURG’s closing price yesterday: http://finance.yahoo.com/news/valeant-pharmaceuticals-acquire-synergetics-usa-120000816.html The nominal deal value is $166M. The VRX roll-up machine keeps on rolling.